基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

休市中 11-06 16:08:52

5.345

-0.290

-5.15%

最高5.625	最低5.200	成交量672.35万
今开5.200	昨收5.635	日振幅7.54%
总市值85.36亿	流通市值85.36亿	总股本15.97亿
成交额3,647万	换手率0.42%	流通股本15.97亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":5.345,"timestamp":1793952532004,"preClose":5.635,"halted":0,"volume":6723479,"delay":0,"changeRate":-0.05146406388642414,"floatShares":1597000000,"shares":1597000000,"eps":-0.314752,"marketStatus":"休市中","change":-0.29,"latestTime":"11-06 16:08:52","open":5.2,"high":5.625,"low":5.2,"amount":36469066,"amplitude":0.075421,"askPrice":5.345,"askSize":14500,"bidPrice":5.315,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":5.635,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.7397288056663721,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年欧洲内科肿瘤学会（European Society for Medical Oncology，ESMO）中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局，III期阳性终点多点开花，持续产出具备国际竞争力的临床数据，标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段，行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320764243.SGD","09688","LU0823426308.USD","LU0708995153.HKD","09926","09995","LU0315179316.USD","01801","02269","IE00BPRC5H50.USD","LU1188198961.HKD","01877","LU0455707207.USD","LU0228659784.USD","BK1574","LU1242518857.USD","LU2097828714.EUR","LU0128522744.USD","LU1960683339.HKD","06160","KCE","LU2242644610.SGD","LU1251922891.USD","LU2488822045.USD","BK1583","BK1191","06185","LU0348783233.USD","LU1226287529.USD","LU0516422952.EUR","LU0594300179.USD","LU1813983027.USD","LU0634319403.HKD","01177","KURE","LU1152091168.USD","LU1152091754.HKD","LU1242518931.SGD","LU1807302812.USD","01093","LU0417516571.SGD","LU0456827905.SGD","LU0540923850.HKD","LU0039217434.USD","02142","601066","BK1515","02616","LU0348766576.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133733427","title":"基石药业-B10月股份变动月报表：新增发行511,875股","url":"https://stock-news.laohu8.com/highlight/detail?id=1133733427","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133733427?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:38","pubTimestamp":1793867918,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年11月5日发布截至2026年10月31日的股份变动月报表。公告显示，公司法定/注册股本维持在2,000,000,000股，每股面值0.0001美元，总额约200,000美元，较上月无变动。报告期内，公司已发行股份由上月底的1,596,330,953股增至本月底的1,596,842,828股，较上月增加511,875股，均为行使于2019年1月30日采纳并于2023年3月7日修订及重列的首次公开发售后员工持股计划所致，对应行权募集资金为483,210港元。截至本月底，公司并无库藏股，亦无股份回购或注销情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680040707","title":"港股异动 | 基石药业-B(02616.HK)涨近4% 与Kimia达成临床开发合作 将共同推进一款具备同类首创潜力药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2680040707","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680040707?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:29","pubTimestamp":1793759373,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680709130","title":"基石药业-B(02616)与Kimia Therapeutics达成临床开发合作，共同推进一款靶向实体瘤关键修复通路的创新候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2680709130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680709130?lang=zh_cn&edition=full","pubTime":"2026-11-04 08:06","pubTimestamp":1793750760,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司已与专注于肿瘤及免疫创新药物研发的生物制药公司Kimia Therapeutics, Inc.达成合作。双方将共同推进一款具备同类首创潜力，靶向实体瘤生存关键DNA损伤应答通路的实体瘤候选药物的临床开发。基石药业将主导该候选药物在中国大陆及澳大利亚的临床开发工作。此次合作进一步印证了业界对基石药业成熟临床开发及药品注册能力的国际认可，也契合公司审慎推进外部创新与全球化布局的战略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4539","BK1574","BK1161","LENZ","BK4139","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678158805","title":"港股异动 | 基石药业-B(02616)早盘涨近7% CS2009取得重大临床验证里程碑并于ESMO 2026公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2678158805","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678158805?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:06","pubTimestamp":1792980405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B早盘涨近7%。截至发稿，涨3.39%，报5.035港元，成交额1921.95万港元。消息面上，基石药业宣布，公司自研PD-1/VEGF/CTLA-4三特异性抗体CS2009取得重大临床验证里程碑，且已在2026年欧洲肿瘤内科学会大会上以两项快速口头报告形式公布最新临床数据。依托来自多种实体瘤、合计超300例受试者的临床数据集，CS2009已同步完成三项关键临床验证：作用机制验证、安全性验证，以及在广谱瘤种中的临床概念验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","KCAI","BK1161","02616","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678804461","title":"基石药业-B(02616.HK)于ESMO 2026公布CS2009关键临床验证数据：逾300例患者数据同步验证作用机制、安全性及广谱抗肿瘤活性","url":"https://stock-news.laohu8.com/highlight/detail?id=2678804461","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678804461?lang=zh_cn&edition=full","pubTime":"2026-10-25 18:31","pubTimestamp":1792924288,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159185562","title":"基石药业-B（02616.HK）公开CS2009逾300例关键临床数据　计划2026年底启动全球Ⅲ期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1159185562","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159185562?lang=zh_cn&edition=full","pubTime":"2026-10-25 18:15","pubTimestamp":1792923357,"startTime":"0","endTime":"0","summary":"2026年10月25日，基石药业-B发布自愿公告称，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009在欧洲肿瘤内科学会2026年年会上以两项快速口头报告形式披露最新关键临床验证结果，累计纳入超300例受试者，完成作用机制、安全性及概念三大核心临床验证。公告称，研究未发现新增安全性信号，CTLA-4及VEGF相关严重毒性发生率均处低水平。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","LU0880133367.SGD","LU0516422440.USD","LU0417516571.SGD","IE0008368742.USD","IBBQ","LU2097828714.EUR","02142","MEDX","09995","LU0456846285.SGD","KCE","LU1770034418.SGD","BK1574","IE00B031HY20.USD","06160","KURE","02616","LU1794554557.SGD","LU0348784397.USD","LU1807302812.USD","600109","01093","LU1303224171.USD","02269","LU0588546209.SGD","BK1141","LNGR","BK1589","01177","LU1951186391.HKD","LU0455707207.USD","LU0540923850.HKD","LU0823426308.USD","LU0228659784.USD","BK0183","LU0128526141.USD","01877","LU0320764599.SGD","LU0516422366.SGD","09688","LU0348783233.USD","LU0128522744.USD","01801","159992","09926","06185","IE00BPRC5H50.USD","IE00B0JY6N72.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","LU2476274720.SGD","LU0181495838.USD","LU0326950275.SGD","159938","LU0228659784.USD","09688","LU0140636845.USD","LU1251922891.USD","LU0979878070.USD","LU1969619763.USD","LU1226287792.SGD","09995","06160","601066","LU1951186391.HKD","SG9999002562.SGD","09926","LU0819121731.USD","LU1226287875.USD","KCE","BK1583","LU0417516902.SGD","LU0348827113.USD","LU1242518857.USD","01177","LU0348767384.USD","01877","02142","SG9999011746.SGD","LU0072913022.USD","LU0540923850.HKD","01801","KURE","LU0501845795.SGD","LU0359201612.USD","BK1610","02616","BK1515","LU0634319403.HKD","02269","IE00BZ08YR35.GBP","LU0052750758.USD","BK1141","01093","09939","LU0128526141.USD","06185","LU0314109678.HKD","LU0823426480.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","AGIX","IBBJ","LU0588546209.SGD","QTOC","LU2242644610.SGD","601066","ARTY","BK1141","02616","LU0051755006.USD","09926","LU0516423174.USD","09688","LU0501845795.SGD","BK1588","LU0516422952.EUR","SG9999002562.SGD","01877","02269","KCE","IE00BZ08YS42.EUR","LU0856984785.SGD","LU2778985437.USD","IE00B031HY20.USD","LU1251922891.USD","BK1576","LU0979878070.USD","09995","LU0456827905.SGD","02142","CHAT","06160","06185","VTHR","LU0326950275.SGD","01801","BK1500","LU0348825331.USD","01177","LU0516422440.USD","01093","LU0456846285.SGD","LU0029874061.USD","KURE","LU0052750758.USD","LU1008478684.HKD","LU0128526141.USD","LU1152091754.HKD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120424983","title":"基石药业-B公布9月股份变动月报 新增7,381股","url":"https://stock-news.laohu8.com/highlight/detail?id=1120424983","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120424983?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:37","pubTimestamp":1791362241,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年10月7日披露了截至2026年9月30日的证券变动月报。2026年9月期间，公司因行使“2019年1月30日采纳并于2023年3月7日修订及重列的首次公开发售后雇员持股计划”而新增发行7,381股普通股。截至本月底，已发行股份总数增加至1,596,330,953股，库存股份仍为0股。公司确认，当月内不存在股份购回、注销或转让自库藏等活动。截至本月末，基石药业-B的公众持股量已符合适用的最低要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673792787","title":"【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2673792787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673792787?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:50","pubTimestamp":1791161445,"startTime":"0","endTime":"0","summary":"随着后续管线商业化兑现、全球创新价值链话语权提升，行业有望迎来业绩与估值的戴维斯双击，创新药板块底部配置价值凸显。中国研究占全体大会核心LBA总量的1/3，这标志着中国肿瘤创新研发已深度融入全球研发体系，成为驱动全球肿瘤诊疗升级的重要力量，持续利好国内创新药企国际化发展与临床价值兑现。2026 ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0315179316.USD","01093","02142","01801","06978","BK1161","01877","LU0455707207.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0043850808.USD","LU0211977185.USD","159992","600109","LU1794554557.SGD","BK1610","KCE","LU0856984785.SGD","09995","LU1807302812.USD","HK0000165453.HKD","LU0359202008.SGD","01177","09926","06160","LU1242518931.SGD","09688","LU1226287875.USD","LU0052750758.USD","IE0008368742.USD","LU0540923850.HKD","LNGR","02616","BK1583","LU0516422952.EUR","LU0314109678.HKD","LU1328277881.USD","06185","LU0823426308.USD","LU2242644610.SGD","BK1576","LU0244354667.USD","BK0201","LU0823426480.USD","IBBQ","LU1226288253.USD","MEDX","02269","KURE","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671956822","title":"港股异动 | 基石药业-B(02616)涨近7% ESMO数据更新在即 高管持续增持彰显发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2671956822","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671956822?lang=zh_cn&edition=full","pubTime":"2026-09-29 14:02","pubTimestamp":1790661761,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨近7%，截至发稿，涨6.81%，报5.49港元，成交额3518.91万港元。此外，公司首席执行官、研发总裁及执行董事杨建新于9月17日至22日以个人资金在公开市场上合共购买49.6万股公司股份，总代价逾270万港元。据悉，自2022年8月担任首席执行官以来，杨建新博士已于公开市场累计购买超1421万股公司股份。此次股份购买充分彰显杨博士对公司的长期承诺以及对公司未来业务前景的坚定信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","02616","BK4588","VXUS","BK1161","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127868216","title":"基石药业-B 2026年中期营收2.05亿元，经调整净亏损2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127868216","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127868216?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:37","pubTimestamp":1790602666,"startTime":"0","endTime":"0","summary":"基石药业-B公布2026年上半年业绩，报告期内公司实现收入2.05亿元，较上年同期的0.49亿元增长约315.2%。该收入主要由药品销售、授权费及特许权使用费构成，其中药品销售额1.83亿元，授权费收入0.07亿元，特许权使用费收入0.15亿元。非国际财务报告准则下，经扣除以股份为基础的付款费用后，期内净亏损从上年同期的2.65亿元收窄至2.31亿元，亏损额减少0.34亿元。经营活动现金流出为2.22亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B 2026年中期营收2.05亿元，经调整净亏损2.31亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192849572","title":"基石药业-B：CEO杨建新博士再斥资逾270万港元增持49.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1192849572","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192849572?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:36","pubTimestamp":1790246181,"startTime":"0","endTime":"0","summary":"基石药业-B9月24日公告称，公司首席执行官、研发总裁兼执行董事杨建新博士于2026年9月17日至22日期间，动用个人资金在公开市场合计增持公司股份496,000股，总代价逾270万港元。公告显示，自2022年8月出任首席执行官以来，杨建新博士已在公开市场累计购入14,210,500股公司股份。公司董事会表示，本次增持体现了杨建新博士对基石药业长期承诺及对未来业务前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669464619","title":"基石药业-B(02616)获首席执行官兼执行董事杨建新增持合共49.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669464619","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669464619?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:33","pubTimestamp":1790245989,"startTime":"0","endTime":"0","summary":"本公司董事会认为，股份购买事项充分体现杨博士对本公司的长期承诺以及对本公司未来业务前景的坚定信心。自2022年8月担任首席执行官以来，杨博士已于公开市场累计购入合共1421.05万股股份。紧随股份购买事项后，杨博士持有合共相当于本公司于本公告日期的已发行股本总额约5.31%的股份。杨博士不排除于适当时候进一步增持本公司股份的可能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","LU2476274720.SGD","02142","01093","LU0314109678.HKD","IBBQ","06160","09995","02269","SG9999002562.SGD","LU0039217434.USD","01801","LU2097828805.USD","KURE","LU1152091754.HKD","600109","MEDX","LU1251922891.USD","LU0828237510.HKD","LU1993786604.SGD","KCE","159992","LU0029874061.USD","06978","LU1226287792.SGD","LU0417516902.SGD","LU1152091168.USD","01877","LU0128526141.USD","LU0359202008.SGD","LU0320764599.SGD","LU0348735423.USD","09688","LU0708995583.HKD","02616","LU0348766576.USD","LU1719994722.HKD","LNGR","BK1515","LU2039709279.SGD","LU3063872942.SGD","LU0315179316.USD","LU1770034418.SGD","01177","06185","HK0000165453.HKD","LU1226288253.USD","LU0516423091.SGD","09926","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996177","title":"执行董事兼首席执行官杨建新增持基石药业-B(02616)13.25万股 每股作价约5.24港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996177","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668996177?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:26","pubTimestamp":1789644373,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月17日，执行董事兼首席执行官杨建新增持基石药业-B13.25万股，每股作价5.2361港元，总金额约为69.38万港元。增持后最新持股数目约为8441.66万股，最新持股比例为5.29%。补充资料：Purchase of shares by Dr. Yang in the open market using his personal funds. Box 28: These shares represent the Restricted Share Units and Share Options that have been granted or are to be issued to Dr. Yang under the Pre-IPO RSU Scheme, the Pre-IPO Share Option Scheme, and the Post-IPO Incentive Schemes.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156279184","title":"基石药业-B：Jianxin Yang增持，好仓比例升至5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156279184","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156279184?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:32","pubTimestamp":1789637521,"startTime":"0","endTime":"0","summary":"Jianxin Yang于2026年9月17日在联交所场内以每股均价5.2361港元买入基石药业-B（02616）股份13.25万股，涉资约69.38万港元，属场内主动交易，即在二级市场直接买卖股份。Jianxin Yang此次增持前持有基石药业-B好仓8428.41万股，占比5.28%；增持后持股量为8441.66万股，好仓比例升至5.29%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0463099449.HKD","09926","LU0181495838.USD","LU0348783233.USD","LU0417516738.SGD","LU0348825331.USD","LU0819121731.USD","LU1820825898.SGD","02616","02269","LU1720050803.USD","BK1141","LU1969619763.USD","LU1813983027.USD","600030","KURE","SG9999004220.SGD","KCE","LU1880383366.USD","09688","LU0516422952.EUR","LU1580142542.USD","LU1961090484.USD","06030","IE00B543WZ88.USD","LU1226287875.USD","LU1794554557.SGD","01093","06185","LU1997245177.USD","LU1226287792.SGD","LU0572944931.SGD","LU2148510915.USD","LU0979878070.USD","LU1064130708.USD","LU1255011170.USD","LU1655091616.SGD","BK1161","02142","LU2039709279.SGD","01801","IE0008369823.USD","01177","BK0028","01877","LU0561508036.HKD","06160","LU0405327494.USD","LU2580892862.HKD","09995"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.082},{"period":"1month","weight":-0.0761},{"period":"3month","weight":0.0171},{"period":"6month","weight":-0.3667},{"period":"1year","weight":-0.0894},{"period":"ytd","weight":0.0142}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.428571,"avgChangeRate":0.066954},{"month":6,"riseRate":0.625,"avgChangeRate":0.030763},{"month":7,"riseRate":0.5,"avgChangeRate":0.038991},{"month":8,"riseRate":0.5,"avgChangeRate":0.110606},{"month":9,"riseRate":0.5,"avgChangeRate":-0.058868},{"month":10,"riseRate":0.375,"avgChangeRate":-0.031011},{"month":11,"riseRate":0.625,"avgChangeRate":0.019345},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}